- 01:10 AM RIL offers to buy Dutch company LyondellBasel
- 05:51 PM In good spirits: Beam Global bets big on India
- 05:47 PM Trellisys.net: Cashing in on the social networking...
- 05:34 PM Obama asks Americans for patience on economy
- 05:34 PM Italy arrests Pakistanis suspected of Mumbai links
- 04:37 PM Govt plans rice reserve sale in local markets
- 04:22 PM Aurobindo Pharma sees $2 bn sales in next 3 ye...
- 04:07 PM Now, Daigeo's duty free products are under DRI len...
- 03:11 PM RBI's new forex derivative rule too liberal, say e...
- 02:30 PM Implications of tax treaty re-negotiation



Mumbai, Aug. 16
Cipla’s paediatric version of triple-combination AIDS drug Triomune can now be purchased by the $15-billion PEPFAR global-initiative to treat the illness. This follows the tentative approval that paediatric Triomune got earlier this week from the US regulatory authority, the Food and Drug Administration (FDA).
Children below 12 years and infected with HIV/AIDS can now receive treatment under the initiative. It is the first fixed dose paediatric AIDS drug to get onto the PEPFAR programme, Mr Amar Lulla, Cipla’s Chief Executive Officer, told Business Line.
In 2003, the US President, Mr George W. Bush had mooted the President’s Emergency Programme for AIDS Relief (PEPFAR) over a five-year period to tackle the illness.
Triomune is a fixed-dose tablet that combines three AIDS medicines — lamivudine, stavudine and nevirapine. Lamivudine is the generic ingredient in GlaxoSmithKline’s AIDS medicine Epivir, stavudine is Bristol-Myers Squibb’s Zerit and nevirapine is Boehringer Ingelheim’s Viramune.
contd on page 2...
|
|
Business
Business News | Economy | Earnings | BSE NSE Notices
General News
Current Affairs | Politics | World News | Sports | Entertainment
Corporate Strategy
Management | Advertising | Marketing | Legal
Personal Finance
Tax | Insurance | Credit Cards | Loans | Property | Retirement | Investment Help | Financial Planning | Fixed Income
Markets
Local Market | Global Market | Market Cues | Analysis | Expert & FII outlook | Brokerage Recomendation
Stocks
Stocks in News | Expert Advice | ADRs & GDRs | IPO
Mutual Funds
News | Advice | MF Analysis | Fund Managers Views
Lifestyle
Travel | Wellness | Technology | Auto| Books
-
Most Read
-
Most Viewed
- 10 Companies that FIIs love
- 10 companies that MF managers love
- 5 stks that were buzzing last week & how to trade them now
- Buy Aban Offshore, target of Rs 2,200: Anand Rathi
- Buy sugar, financials, pharma on declines: Experts

- Sensex ends over 200 pts up led by banks, oil & gas, metals
- Cox and Kings IPO subscribed 6.31 times
- Bharti Airtel reduces roaming charges to 50 paise/min

- In good spirits: Beam Global bets big on India
Source: CNBC-TV18
- Trellisys.net: Cashing in on the social networking craze
Source: Moneycontrol.com
- Aurobindo Pharma sees $2 bn sales in next 3 years
Source: CNBC-TV18
- Now, Daigeo's duty free products are under DRI lens
Source: Moneycontrol.com
- HDFC Standard Life plans IPO in 2010-11
Source: Business Line
- GM India will not cede ground in Chinese alliance
Source: Business Line
- Spices export rises in Oct
Source: Business Line
- Bharat Hotels to invest Rs 2,300 cr in new properties
Source: Business Line






















